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Capecitabine, a 5-ﬂuorouracil prodrug, is increasingly used in breast cancer due to its more convenient
oral route of administration compared to 5-ﬂuorouracil. Despite its widespread use, there are only a few
reports on low-dose efﬁcacy, while the clinical signiﬁcance of such agents remains to be illustrated. Here,
we report two cases of breast cancer in women older than 85 years. Both were treated with capecitabine
500 mg t.i.d. every day for 9 and 12 courses, respectively; each course was 21 days. After treatment with
low-dose capecitabine, both patients achieved partial tumor response. The side-effects were analyzed
during chemotherapy; the primary adverse effects included mild fatigue, loss of appetite, and diarrhea. In
conclusion, we observed that the administration of low-dose metronomic capecitabine improved two
elderly patients with advanced breast cancers. It might be a well-tolerated treatment option, but its
clinical signiﬁcance still remains to be explored in large scale cohorts.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
With lifetime extension, the morbidity of breast cancer is
increasing in elderly women1. Age is a major risk factor for breast
carcinoma: women aged 75 years and older have higher incidence
and mortality rates compared with younger women2. As a result,
most cases of elderly breast cancer are diagnosed at a later stage.
Furthermore, many patients have a metastatic tumor3. However,
oncologists have been reluctant to enroll older women onto clinical
trials, and there is a lack of adequate guidelines for the manage-
ment of this age group.
The primary purposes of chemotherapy are to improve prog-
nosis and alleviate tumor-related symptoms and complications4.
Palliative chemotherapy is the ﬁrst-line treatment of choice for
estrogen receptor (ER) positive older patients with advanced breast
cancer. By contrast, hormone receptor-negative progressive disease
refractory, and life-threatening metastases tumors adopted to
endocrine therapy, or are likely to be more effective5,6. For fear ofof interest to declare.
ast, Sichuan Cancer Hospital,
tric Emergency & Critical Care Med
es/by-nc-nd/4.0/).excessive toxicity from chemotherapy, elderly patients often suf-
fered from suboptimal chemotherapy. Thus, there is great interests
in single-agent chemotherapy for elderly breast cancer patients.
Capecitabine, an orally administered ﬂuoropyrimidine carbamate,
shows effective curative effects in the monotherapy for advanced
breast cancer.7 Few studies have been conducted to determine the
clinical signiﬁcance of low-dose capecitabine in the chemotherapy
for elderly patients with advanced breast cancer. Herein, we
describe two female patients older than 85 years with advanced
breast cancer and their clinical outcomes after being subjected to
low-dose capecitabine.2. Case presentation
2.1. Case 1
A 92-year-old woman suffered cancer in the left breast, and left
nipple retraction with a 7.5 cm mass. The lesion protruded 1.5 cm
from the skin's surface, accompanied with visible exudate leakage
along the lesion. She was found to have ﬁrm, ﬁxed, and left
enlarged axillary lymph node, 1.5 cm in diameter. There was no
evidence to prove anymetastatic lesions based on chest radiograph,
abdominal ultrasonography, or bone scan. Ultrasound-guided core-icine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
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cinoma. At the same time, the ﬁne needle aspiration also indicated
a positive diagnosis of malignant lesion. The immunohistochemical
staining revealed ERþ (> 90%), progesterone receptorþ (50%), and
c-erbB-2þ.
Initially, she was treated with anastrozole (1 mg) every day.
Three months later, there were no obvious changes in tumor size or
enlarged lymph node, which indicated that the regimen failed to
beneﬁt this patient. Therefore, she was further treated with low-
dose oral capecitabine (500 mg t.i.d.) daily. For each cycle, she
took the medicine < 30 minutes after meals for 21 days. Treatment
was continued unless disease progression or unacceptable toxicity
occurred. A total of 12 cycles were administered. The side-effects of
the patient included mild fatigue and loss of appetite in the third
cycle. Response was assessed on contrast enhanced computed to-
mography according to RECIST 1.1 criteria8 after Cycles 2 and 4, and
3 months after Cycle 12. However, the size of the breast was were
decreased after treatment for 1 month. More importantly, the tu-
mor had shrunk and the results of blood count tests were normal.
Her liver and renal function were also without any abnormal
symptoms. Nevertheless, she died of pneumonia caused by an
inﬂuenza virus.
2.2. Case 2
Another female breast cancer patient, aged 87 years, had a
malignant lesion on the left with a length of 3 cm. She was proved
by needle biopsy to have invasive lobular carcinoma. Immunohis-
tochemical staining showed that the three biomarkers were posi-
tive [ERþ (5%), progesterone receptor, and c-erbB-2þ]. She had
self-medicated by administering tamoxifen for 3 years without
any guidance from oncologists. Recently, the patient complained of
a chronic cough and thus came to see a physician. The following
physical examination indicated a 4 cm mass on the left breast, left
nipple was retracted, and axillary lymph nodes were not palpable.
Computed tomography detected two lesions located in left lung
with diameter of 2.5 cm. Initially, she was treated with anastrozole
in a dose of 1 mg daily. These drugs failed to bring any beneﬁts and
no obvious reduction of the tumors in the breast or lung after
treatment for 2 months.
She was administered with same chemotherapy regimen as
mentioned above and a total of nine cycles were completed. The
chemotherapy response also been assessed according to RECIST 1.1
criteria after Cycles 2 and 4, and 3 months after Cycle 9. As a result,
either primary tumor or pulmonary metastases lesions were
decreased. She complained of mild fatigue and diarrhea when in
the second cycle of chemotherapy. At the same time, the blood
count test, and liver and renal function all indicated normal phys-
ical symptoms. She had to be hospitalized because of Grade 2
diarrhea after ﬁnishing nine cycles of chemotherapy. Finally, she
died of heart failure.
3. Discussion
In regard to chemotherapy for elderly patients with breast
cancer, it is very important to balance high treatment efﬁcacy and
acceptable treatment-related toxicity. Mostly elderly patients al-
ways become resistant to chemotherapy drugs, but are sensitive to
hormone therapy, especially triple positive patients.9 Thus, endo-
crine therapy should be the preferred for those patients.10 However,
elderly patients with advanced breast cancer, such as ER or
advanced stage tumors, are refractory to endocrine therapy, so
chemotherapy should be the unique way to prolong life. Single-
agent chemotherapy with low dose6 could be a reasonable
approach because it is less toxic, in the condition to yield similarclinical outcomes.5 In the present report, the most common
adverse events associated with capecitabine, including handefoot
syndrome, nausea, and vomiting were not observed in either case.
Capecitabine has been proven effective and well-tolerated in
curing metastatic breast cancer, metastatic colorectal cancer, or as
an adjuvant treatment for colon cancer.7 Capecitabine has sub-
stantial antitumor activity in metastatic breast cancer, with
response rates of approximately 30%.11,12 Capecitabine showed
similar clinical efﬁciency as CMF (cyclophosphamide, metho-
trexate, ﬂuorouracil) chemotherapy in the treatment for metastatic
breast cancer.13 Based on our observations, low-dose capecitabine
had acceptable side effects and effectively prevents progress of
advanced breast cancers in elderly women.
The recommended regimen of capecitabine is 1250mg/m2 b.i.d.,
on Days 1e14, every 21 days. At this condition, about 65% of pa-
tients have to decrease to 25% dose due to intolerable side-ef-
fects.12,14,15 Many reports, however, have indicated that a low dose
could offer better tolerability without compromising efﬁcacy.2 For
example, it was reported that the chemotherapy regiment of
capecitabine (828 mg/m2 b.i.d., on Days 1e21, every 28 days) same
efﬁciencies as the high-dose regimen in Japan.15 In a randomized
trial, Stockler et al reported that capecitabine in a dose of 650 mg/
m2 b.i.d. was equally effective as conventional CMF
chemotherapy.16
4. Conclusions
In our study, both advanced breast cancer patients treated with
low-dose capecitabine showed improved activities of daily living
and quality of life. In palliative oncology, it is suggested that lower
dosing of capecitabine monotherapy might be still active in control
of the disease with minimal toxicity and might be considered as a
viable option for palliative management of advanced elder breast
cancer. However, the efﬁcacy and superiority in fragile elderly pa-
tients remain to be explored in large prospective randomized trials.
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